Current Status of Endovascular Stroke Treatment

Philip M. Meyers, MD, FAHA; H. Christian Schumacher, MD; E. Sander Connolly, Jr, MD; Eric J. Heyer, MD, PhD; William A. Gray, MD, FAHA; Randall T. Higashida, MD, FAHA

Stroke is the third-leading cause of death in the United States, Canada, Europe, and Japan. According to American Heart Association statistics, there are now 795,000 new strokes each year, resulting in 200,000 deaths, or 1 of every 16 deaths, per year in the United States. Ischemic stroke represents 80% of the total, and hemorrhagic stroke makes up the remainder. Stroke is the leading cause of adult disability in both North America and Medicare reimbursement for long-term adult care. The National Institutes of Health (NIH) estimate that stroke costs exceed $73 billion in US healthcare dollars per year. Improved treatments are needed to reduce the burden of human suffering and to lessen the financial burden on society.

Epidemiologically, there are 795,000 strokes per year in the United States, but this number does not represent the number of treatable strokes. The real number of ischemic strokes amenable to some form of endovascular revascularization intervention is probably a small subset of the total number. This disparity explains, at least in part, the relatively slow progress in stroke trial enrollment and scientific progress compared with the more rapid development of cardiac interventions. The number of acute strokes potentially requiring emergent intervention ranges from 58,000 to 120,000 per year, or 7% to 15% of the total number, because many acute ischemic strokes are due to hemorrhage, small-vessel occlusions (lacunar strokes), transient ischemic attacks, end-of-life strokes, and mild strokes that do not warrant the risk of an endovascular procedure. In most communities, only 1% to 7% of stroke victims arrive at hospital in time for stroke revascularization therapies. Even in communities with highly organized and active stroke programs, <10% of stroke victims receive immediate treatment. Even if such programs were instituted across the United States, ≈58,000 stroke victims (9% of 645,000 ischemic stroke patients) would receive treatment. The number potentially needing an endovascular intervention is less clear. Extensive brain injury is already present in many patients on admission. In comprehensive stroke centers following evidence-based guidelines for intervention, endovascular ischemic stroke procedures remain among the least common procedures that neurointerventionalists perform (on average, 8 procedures per year). The reason is that 20% of strokes are due to small-artery occlusions (lacunar strokes), and another 20% to large-artery occlusions causing severe strokes.

We have organized this review as follows. First, we discuss stroke imaging, because it emphasizes the essential problem in distinguishing ischemic penumbra, which is potentially recoverable cerebrum, from infarcted cerebrum, which is not recoverable. Second, we review intravascular fibrinolytic therapies, intravenous and intra-arterial fibrinolysis. Third, we describe mechanical revascularization therapies, including thromboembolectomy, suction thrombectomy, angioplasty and stent revascularization, and the new stent-retriever thrombectomy. Finally, we discuss the potential futility of some of these therapies without further scientific advancements.

Stroke Imaging

Neurological imaging has developed rapidly over the last 20 years, but stroke physiology is complex. Acutely injured but salvageable brain tissue is not clinically discernable from irrevocably infarcted tissue by physical examination. Most stroke patients will present with some core infarct that cannot be restored even by the most rapid intervention. When present, there is strong evidence that tissue with impaired blood flow surrounding the core infarct may be saved by early intervention. This so-called ischemic penumbra will progress to infarction without rapid revascularization. In contrast, an infarct without penumbra will not improve with intervention, and patients may actually be harmed by procedural revascularization causing hemorrhagic transformation. Modern imaging may provide information to draw this important distinction and to guide emergency triage.

The distinction between hemorrhagic and ischemic stroke is pivotal in the management of acute stroke. All major stroke trials have relied on the sensitivity and availability of the nonenhanced computed tomography (CT) brain scan primarily for the presence of acute hemorrhage to determine patient enrollment. Thus, most knowledge about the imaging manifestations of acute ischemic stroke and response to treatment is based on the simplest form of CT imaging. Ease of access, rapid scan time, and broad availability mean that CT remains
the most commonly used form of acute stroke imaging and has the highest level of evidence. Therefore, nonenhanced CT brain scan remains the only cerebral imaging test required before intravenous administration of recombinant tissue-type plasminogen activator (rtPA).

Magnetic resonance imaging (MRI) has specific advantages and disadvantages compared with CT. Diffusion-weighted imaging has proven to be both sensitive and specific to the presence of early cerebral ischemia. Recent evidence suggests that MRI may also be as sensitive to the presence of acute hemorrhage as CT. Thus, MRI may be used as the primary imaging modality to assess patients with suspected acute stroke instead of CT. The disadvantages remain limited availability, longer scan times, and the incompatibility of the magnetic environment with iron-containing medical equipment and conductive bioprosthesis (eg, cardiac pacers, internal defibrillators).

An optimal form of cerebral viability imaging remains elusive, and research is ongoing. The goal is to identify and measure the volume of brain tissue irreversibly damaged and tissue at risk for infarction that remains potentially salvageable. Now, CT angiography rivals the quality of diagnostic catheter angiography to assess for large cerebral artery occlusion, and CT perfusion imaging measures mean contrast transit time, relative cerebral blood volume, and relative blood flow. With contrast-enhanced MRI, perfusion-weighted imaging also permits determination of mean contrast transit time, relative cerebral blood volume, and relative cerebral blood flow. Comparison of perfusion data representing the ischemic penumbra with diffusion-weighted images representing the core infarct should allow physicians to make treatment decisions regarding the likely risks and benefits of intervention. In fact, some investigators have argued that use of the time interval from stroke onset to guide therapy should be abandoned in preference for imaging analysis of core infarct volume in relation to ischemic penumbra.

The significance of perfusion imaging and its relevance to stroke pathophysiology are the subject of vigorous debate. The complexity and variability of cerebral circulation, including leptomeningeal, circle of Willis, and external carotid artery collaterals, mean that perfusion data remain difficult to apply to treatment of individual patients. Concerns about stroke application and misapplication persist. Analysis of perfusion-perfusion mismatch to guide stroke treatment shows benefit in some studies, and is the subject of the ongoing NIH-funded Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR-RESCUE) trial. Meanwhile, other studies have shown that perfusion imaging does not correlate well with the physiological parameters of cerebral ischemia it purportedly predicts, and diffusion-perfusion mismatch has not been shown to effectively differentiate between salvageable and unsalvageable tissue. For these and other reasons, the Advanced Neuroimaging for Acute Stroke Treatment group proposed the establishment of an Acute Stroke Imaging Consortium to facilitate the development and validation of advanced stroke imaging.

The problem with the revascularization therapies that we discuss here is that infarcted cerebrum will not recover, yet tissue in the ischemic penumbra might recover if rescued in time. Unfortunately, that window of time is uncertain, and probably varies significantly from patient to patient. Great harm can occur if inappropriate revascularization results in hemorrhagic transformation of an ischemic infarct. The concern is that enthusiasm for the development of new treatment strategies has the potential to distort and exaggerate scientific research. It is important to evaluate and test the significance of stroke trial results rigorously so that there is not a movement to prematurely expand the indications and applications of treatment methods that may not yet be broadly effective. Meanwhile, stroke patients who might achieve good recovery despite presentation outside the confines of conventional treatment paradigms should not be overlooked. Their treatment should be the subject of additional carefully designed clinical trials.

### Intravenous Fibrinolysis

In any review of endovascular stroke therapy, there are important reasons to initiate the discussion with intravenous therapy for acute ischemic stroke. Intravenous fibrinolysis with rtPA remains the only Food and Drug Administration (FDA)-approved treatment (Level of Evidence 1, Class A recommendation) for stroke patients presenting within 3 hours after onset based on the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study (NINDS rt-PA). The European Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) registry enrolling 6483 patients confirmed the safety and efficacy of intravenous fibrinolysis (Table 1). Pooled analysis of 6 major trials showed that there could be additional benefit beyond the 3-hour limit despite increased risk. The European Cooperative Acute Stroke Study III (ECASS3) has now shown the safety and efficacy of intravenous thrombolysis with alteplase for ischemic stroke in selected patients treated 3 to 4.5 hours after stroke onset. Although many endovascular treatment protocols were originally designed with a 3-hour limitation for intravenous fibrinolysis in mind, the new 4.5-hour treatment horizon for selected patients should probably replace the 3-hour limit. Moreover, the latest AHA guidelines state that availability of endovascular treatment services should not supersede the use of intravenous fibrinolysis when indicated.

### Intra-Arterial Therapies

Endovascular therapy for patients with acute ischemic stroke is currently an area of intense investigation. An Accreditation Council for Graduate Medical Education–approved training pathway was developed to train physicians for endovascular treatment of cerebrovascular diseases, including ischemic stroke. Training criteria and standards of performance for endovascular stroke treatment are summarized in a consensus document. The American Stroke Association has given qualified endorsement of intra-arterial fibrinolysis, despite its lack of scientifically proven efficacy in >1 trial. Intra-arterial fibrinolysis has been studied in several randomized trials and numerous case series but proven according to FDA standards.
in only 1 trial using prourokinase, a drug no longer available.⁴ Thus, intra-arterial fibrinolysis has the status of community standard in many locales, but remains an off-label application of any available fibrinolytic agent requiring further experimental proof of safety and efficacy for on-label application. Similarly, 2 devices have been granted US FDA approval with an indication for mechanical stroke thrombectomy, but no thrombectomy device has yet been scientifically proven to improve patient outcomes.

It has been recognized for nearly 20 years that intravenous fibrinolysis is less likely to recanalize large cerebral artery occlusions. Intravenous fibrinolysis is time-consuming, and the action of fibrinolytic agents may take ≥2 hours.⁵ Oclusions in more proximal locations, including the intracranial internal carotid artery and proximal middle cerebral artery, are more resistant to intravenous delivery of lytic agents, with only 8% to 12% probability of early recanalization.⁶ In contrast, intra-arterial administration of fibrinolytic agents has been shown to significantly increase the chances of recanalization.⁴

Although intra-arterial fibrinolysis has been used for nearly 3 decades and has shown apparent benefit in case series, Prolyse in Acute Cerebral Thromboembolism II (PROACT II)⁷ is the only randomized trial to date on the safety and efficacy of intra-arterial fibrinolysis in acute ischemic stroke. In this study, 12 323 stroke patients were evaluated to identify 180 eligible patients with proximal middle cerebral artery occlusions (1.4% of screened patients). Patients were randomized to treatment with intra-arterial prourokinase with intravenous heparin alone. More than 10 years later, 66% recanalization and 40% good neurological outcomes achieved in PROACT II remain the yardstick by which newer endovascular methods are judged. Although higher rates of recanalization have been accomplished in more recent trials, 40% favorable neurological outcomes and 25% mortality remain the standard for new devices and techniques even a decade later (Table 1).

The EKOS MicroLySUS infusion catheter (EKOS Corp, Bothell, WA) was designed to augment intra-arterial fibrinolysis by creating local convection currents at the site of occlusion using low-intensity, high-frequency ultrasound. This facilitates diffusion of the lytic agent into the thrombus, increasing its effective surface area of interaction. A phase I trial reported preliminary results in 14 patients with 60% recanalization at 60 minutes despite treatment of large clot burdens in some patients.³² The device was tested again in Interventional Management of Stroke (IMS) II³³ with promising results (Table 1), and is an option for use in the NINDS rt-PA-funded IMS III trial,³⁴ which is currently enrolling at 60 stroke centers worldwide.

The data on intra-arterial fibrinolysis for vertebrobasilar occlusion are limited. Mostly because neurological outcomes are abysmal without treatment, review of the literature generally supports potential benefit even as long as 18 to 24 hours after symptom onset.³⁵ A meta-analysis of multiple case series comparing intravenous with intra-arterial fibrinolysis for acute vertebrobasilar stroke in 422 patients showed marginally better recanalization rates with intra-arterial therapy (65% versus 53%; P = 0.5), good neurological outcomes in 22% to 24% of patients, but no clear difference in efficacy between the 2 modalities.³⁶ Similar findings were demonstrated in 400 patients in the Basilar Artery International Cooperative Study (BASICS) trial.³⁷

Lee et al⁴¹ performed a meta-analysis of randomized, controlled trials evaluating intra-arterial fibrinolysis for acute ischemic stroke. To date, PROACT II remains the only randomized, controlled trial of intra-arterial fibrinolysis to show a statistically significant clinical benefit.⁴ Four other trials demonstrated trends in favor of intra-arterial fibrinolysis, but were inadequately powered to demonstrate statistically significant improvement in neurological outcomes. For this reason, meta-analysis of combined data on 395 patients from 5 trials provides a strong indication of statistically significant good (odds ratio, 2.05; 95% confidence interval, 1.33 to 3.14; P = 0.001) and excellent (odds ratio, 2.14; 95% confidence interval, 1.31 to 3.51; P = 0.003) outcomes.³¹

Lee et al⁴¹ noted an interesting discrepancy between recanalization of occluded cerebral arteries and clinical out-
comes. Intra-arterial fibrinolysis was associated with an absolute increase in the rate of partial or complete vessel recanalization (46.8%) over placebo therapy. Yet, the rate of recanalization is 3 times higher than the absolute increase in good (14.8%) or excellent (13.0%) clinical outcomes. Although recanalization and reperfusion are presumably benefits of intra-arterial fibrinolysis, these authors speculate that the disparity is due to either limitations in the outcome measurement tools to adequately detect real clinical improvement in stroke victims or completion of stroke injury before revascularization and reperfusion. The gap between recanalization and clinical improvement becomes more pronounced during the evaluation of mechanical revascularization studies performed up to 8 hours after stroke onset (Table 1 and Figure 1). Ultimately, this issue must be addressed for endovascular stroke therapies to succeed. Patient selection for treatment still needs to be defined, which may be the role for advanced brain viability imaging.

**Mechanical Revascularization**

### Thromboembolectomy

Broadly speaking, spontaneous or therapeutic recanalization and reperfusion in acute ischemic stroke are associated with improved functional outcomes and reduced mortality in a meta-analysis of 53 studies. For patients who are ineligible for fibrinolytic therapy, those with large-artery occlusions and severe stroke disability, alternative methods of treatment are under investigation. Mechanical thrombectomy devices specifically for acute stroke intervention were first developed in the 1990s as engineering technologies for fabrication of microcatheters and guidewires specifically amenable to cerebral navigation improved. Mechanical devices offer theoretical advantages over pharmacological treatment, potentially including speed of recanalization, revascularization of large-artery occlusions, reduced risk of hemorrhage compared with lytics, and longer time window for use.

Foreign-body retrieval devices for endovascular application were first reported in the 1980s. A broad variety of devices were used off-label for attempted stroke thromboembolectomy. Seven retrieval devices were evaluated for stroke applications in actual studies. Only 2 devices (Concentric MERCI and Penumbra Suction Thrombectomy System) to date have sought and received FDA approval as foreign-body retrievers with stroke indication. Procedural success is usually measured primarily by vessel recanalization. In fact, most stroke thrombectomy trials have focused on local recanalization of the occluded brain artery and defined procedural success by partial or complete recanalization only.

**Figure 1.** Higher rates of recanalization, approaching 90% in the Penumbra Pivotal Trial, do not correspond with similar rates of clinical improvement after treatment as measured by the modified Rankin scale (mRS) at 90 days. NIHSS indicates National Institutes of Health Scale; TIMI, Thrombolysis in Myocardial Infarction; PROACT II, Prolyse in Acute Cerebral Thromboembolism trial; IMS, Interventional Management of Stroke; and MERCI, Mechanical Embolus Removal in Cerebral Ischemia.
Table 2. Major Trials of Mechanical Devices for Treatment of Acute Ischemic Stroke

<table>
<thead>
<tr>
<th>Major Mechanical Thrombectomy Device Studies</th>
<th>MERCI Pilot</th>
<th>MERCI 1</th>
<th>Multi-MERCI</th>
<th>PENUMBRA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>28</td>
<td>151</td>
<td>164</td>
<td>125</td>
</tr>
<tr>
<td>Age (mean), y</td>
<td>68</td>
<td>67</td>
<td>68</td>
<td>64</td>
</tr>
<tr>
<td>NIHSS</td>
<td>22</td>
<td>20</td>
<td>19</td>
<td>18</td>
</tr>
<tr>
<td>Time to treatment, h</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>From presentation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>From groin puncture</td>
<td>2.5</td>
<td>4.3</td>
<td>4.3</td>
<td>4.3</td>
</tr>
<tr>
<td>Recanalization (TIMI 2–3), %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Device only</td>
<td>43</td>
<td>46</td>
<td>57</td>
<td>82</td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td>64</td>
<td>69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complications, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1</td>
<td>13</td>
<td>9.8</td>
<td>13</td>
</tr>
<tr>
<td>Clinically significant</td>
<td>7.1</td>
<td>5.5</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>Hemorrhage, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>43</td>
<td>7.8</td>
<td>9.8</td>
<td>28</td>
</tr>
<tr>
<td>Clinically significant</td>
<td>0</td>
<td></td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>Outcome (mRS 0–2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 30 d</td>
<td>20</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 90 d</td>
<td>28</td>
<td>36</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Mortality, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 30 d</td>
<td>36</td>
<td>37</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>At 90 d</td>
<td>43</td>
<td>43</td>
<td>34</td>
<td>33</td>
</tr>
</tbody>
</table>

MERCI indicates Mechanical Embolus Removal in Cerebral Ischemia; NIHSS, National Institutes of Health Stroke Scale; TIMI, Thrombolysis in Myocardial Infarction; and mRS, modified Rankin Scale.

at the site of occlusion. Fragmentation, distal embolization, or relocation of the occlusive thrombus is usually not part of the primary outcome measure, which may partially explain limitations in clinical outcomes after treatment.37

The Mechanical Embolus Removal in Cerebral Ischemia (MERCI; Concentric Medical, Inc, Mountain View, CA) device was first to market, and probably remains the most widely distributed stroke retriever. A venture capital–funded endeavor, Concentric Medical, was the first to seek a stroke indication for its foreign-body retriever. By crossing the site of occlusion, this corkscrew-shaped device pulls the occlusive thromboembolus into an extracranial guide catheter under active suction. Successive generations of the MERCI device have been reported in 3 prospective, single-arm, nonrandomized, multicenter feasibility, and safety studies (Table 2). Patients enrolled in these studies were ineligible for intravenous fibrinolysis or had failed to respond to intravenous fibrinolysis. Enrolled patients were treated within 8 hours of stroke onset. On average, treatment began 4.3 hours after stroke onset. Recanalization, if achieved, occurred by 5.9 hours. Primary outcome measures included partial or complete recanalization of the occlusion (Thrombolysis in Myocardial [TIMI] grade 2 to 3) and safety. Secondary outcomes included clinical outcome (stroke, myocardial infarction, death) at 30 and 90 days.38 Multivariate analysis demonstrated that recanalization was associated with good outcome, whereas increased age and stroke severity were associated with poor outcome and death. Apparent limitations include operator learning curve, need to traverse the occluded artery to deploy the device distal to the occlusion, duration required to perform multiple passes with the device, clot fragmentation, and embolization.

Suction Thrombectomy

The Penumbra stroke system (Penumbra, Inc, Alameda, CA) is increasingly popular and uses 2 types of devices to remove occlusive thromboembolus in acute ischemic stroke. An alternate strategy, the Penumbra devices act on the proximal face of the occlusion without traversing the occluded artery. An aspiration device is used to debulk and extract the clot. A second retriever device resembling a stent attached to a guidewire is used to remove resistant clot. Like the Concentric device, the time window for application remains 8 hours after stroke onset in patients who are ineligible for or failing intravenous fibrinolysis (Figure 2).

The Penumbra Pivotal Stroke Trial was a prospective, single-arm, multicenter study that showed a high rate of TIMI grade 2 to 3 recanalization in 81.6% of treated vessels. Yet, good clinical outcomes at 90 days (modified Rankin Scale [mRS] score, 0 to 2) still occurred in only 25% of patients. Both Penumbra devices received the CE mark in Europe; however, only the suction catheter system has received US FDA 510(k) approval.39 This study showed a significant improvement in the rate of local recanalization compared with previous studies using devices and fibrinolytic agents. Although recanalization correlated with improvements in patient outcome (>4 points on the NIH Stroke Scale [NIHSS] in 57.8%; mRS score, 0 to 2 in 25%), the relationship is not linear, and was less than expected. Efforts to address the disparity include questions about the adaptation and application of the TIMI scoring system for recanalization in cerebrovascular occlusive disease instead of cardiovascular disease.40 Limitations in clinical outcomes may reflect local recanalization with extensive distal embolization of the vascular tree, analogous to no reflow described in the cardiologic literature.

The relatively fewer good outcomes compared with prior reports using other methods such as intra-arterial fibrinolysis without mechanical interventions (Table 2) have led some to question the efficacy of mechanical methods without rigorous inquiry.41 The Agency for Healthcare Quality and Research, a division of the Department of Health and Human Services that advises the Center for Medicare and Medicaid Services, issued a technical brief on the current status of stroke therapy using neurothrombectomy devices. Originally available for consumer review on the Agency for Healthcare Quality and Research Web site (http://www.ahrq.gov/), this review has been published.42 The analysis concludes that there is a paucity of high-quality research, many unanswered questions, and a need for further research to determine the optimal device(s), their efficacy, and their safety. Although physicians may express reservations about the Agency for Healthcare Quality and Research review because it potentially...
jeopardizes reimbursement for endovascular stroke therapy, few can argue the interpretation of the data and the concerns it raises.

**Angioplasty and Stent Revascularization**

Angioplasty is now commonly used in stroke revascularization, and is occasionally followed by stenting. It has been performed most commonly as a rescue procedure to displace thrombus or following early reocclusion after successful fibrinolysis. Angioplasty with stenting was originally described in acute stroke for underlying atherosclerotic stenosis after successful fibrinolysis. Stenting at the time of acute stroke has been used most frequently in Asia, where intracranial atherosclerotic disease is the most common cause of acute ischemic stroke. Recanalization rates with angioplasty are high with or without accompanying fibrinolysis, ranging from 60% to 90% and good outcomes (mRS score, 0 to 2 or NIHSS \leq 4) between 36% and 74% in 2 small series.

Stent revascularization in the cerebral circulation is an off-label application of these devices. For subacute cerebral ischemia resulting from symptomatic intracranial atherosclerotic disease, stent revascularization with the Wingspan device (Stryker/Target, Fremont, CA) is the subject of the ongoing NIH-funded Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. In this study, stent angioplasty with the Wingspan device plus medical therapy was compared with medical therapy alone for the treatment of severe (\geq 70% stenosis) symptomatic intracranial atherosclerosis. Natural history data about intracranial stenosis treated with medical therapy appear similar to the risk of treatment with stent angioplasty in multicenter registries. Moreover, strong antithrombotic agents commonly used at the time of coronary stent revascularization with minimal risk of cerebral hemorrhage may result in unacceptable risk of hemorrhagic complications when applied to cerebral ischemic disease. Nevertheless, a number of authors have reported dramatic success using stents to treat acute ischemic stroke despite the foregoing concerns. No NIH-funded trial of cerebral stenting in acute ischemic stroke has been approved at this time (Figure 2).

**Stent Retriever Thrombectomy**

To avoid the need for strong antithrombotic medications such as P2Y12 or glycoprotein IIb/IIIa inhibitors for cerebral stent implantation in acute thromboembolic stroke, a number of companies have developed hybrid devices combining the features of removable cerebral stents and clot retriever devices. For this reason, these devices are sometimes referred to as stent retrievers. Examples include the Solitaire (Covidien/eV3, Maple Grove, MN), now undergoing testing in the Solitaire FR With the Intention for Thrombectomy (SWIFT) trial; Trevo (Concentric Medical Inc, Mountain View, CA), now undergoing testing in the Thrombectomy Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke (TREVO) trial in the United States and Europe; and pilot studies on a number of similar devices at earlier phases of development. Seifert et al reported on the use of the Solitaire device in conjunction with intravenous or intra-arterial fibrinolysis in 4 patients, achieving TIMI grade 2 to 3 recanalization in all patients and clinical improvement (mRS score, 1 at 30 days) in 50%. There was 1 death, and the other patient was lost to follow-up. Similarly, Castano et al
reported pilot data using the Solitaire device in 18 patients for the treatment of acute ischemic stroke (mean NIHSS score, 19) within 8 hours of stroke onset and accomplished TIMI grade 2 to 3 recanalization in 90% without adjuvant therapy in 50 minutes on average and good outcomes (mRS score, 0 to 2 at 90 days) in 45%. Ten percent of patients experienced hemorrhages and 20% died within the follow-up period. Questions remain about the study designs used for FDA or CE device approval in which local recanalization is used as a surrogate marker for clinical recovery after stroke revascularization.

**Futile Recanalization**

Although recanalization rates in several studies correlate with favorable neurological outcome and functional recovery, the risk of death remains stable despite recanalization. Death occurs in 26% to 36% of treated patients across many studies (Figure 4). The most likely explanation is that the variability from patient to patient in the presence of good collateral cerebral circulation beyond an occlusion during an acute thromboembolic stroke may be the underlying cause. Collateral circulation to vessels beyond an acute occlusion may potentially sustain tissue viability until recanalization occurs. However, these collaterals are not universally present. Moreover, collateral channels may become overwhelmed when the site of occlusion is proximal because of the larger volume of ischemic brain tissue and prolonged time to revascularization. Baseline clinical conditions such as diabetes mellitus, hypertension, and patient age may directly or indirectly affect the quantity and quality of collateral vasculature. Predictors of futile recanalization have been independently associated with age >70 years, NIHSS score of 10 to 19, and NIHSS score >20. Although there was no clear effect of time to treatment across studies, this may be attributable to the heterogeneity of the studies analyzed (Figure 5). Therefore, careful patient selection for stroke intervention based
on collateral circulation using some form of viability imaging remains a critical component to improve clinical outcomes, and is the reason that stroke intervention should remain a research protocol.53

For this reason, among others, investigators at the University of Houston (Houston, TX) and University of California Los Angeles have focused on identifying predictors of poor outcome after intra-arterial therapy. The goal was to develop a scoring system that could accurately stratify patients at high risk for futile recanalization. The University of Houston group developed a simple scoring system called the Houston Intra-Arterial Therapy (HIAT) score that was based on a retrospective analysis of 190 patients who underwent intra-arterial therapy at their center from 1998 to 2007. The HIAT score was then retrospectively applied to a different group of 175 patients treated with intra-arterial techniques between

**Figure 4.** A 13-year-old boy with complex cyanotic heart disease develops acute aphasia and right hemiplegia (National Institutes of Health Stroke Scale score, 26) 4 days after a fenestrated Fontan procedure. The patient was ineligible for intravenous fibrinolysis, and was taken immediately for endovascular treatment within an hour of stroke onset. **A** and **B,** Left internal carotid arteriography shows proximal occlusion of the left middle cerebral artery (arrow in image A; ellipsoid in image B). **C,** Computed tomography brain scan after rapid revascularization shows no evidence of stroke or hemorrhage (arrows in **D** and **E**). However, the patient did not improve clinically. **F,** Repeat computed tomography at 24 hours shows extensive infarction with hemorrhagic conversion. The family withdrew care, and the patient died.

**Figure 5.** Mortality occurs in approximately one third of stroke patients and symptomatic intracranial hemorrhage (ICH) in ~10% treated with endovascular procedures despite a trend toward higher rates of recanalization and a reduction in the use of fibrinolysis agents. NINDS rt-PA indicates National Institute of Neurological Disorders Tissue Plasminogen Activator for Acute Ischemic Stroke Trial; rtPA, recombinant tissue-type plasminogen activator; PROACT II, Prolyse in Acute Cerebral Thromboembolism trial; and MERCI, Mechanical Embolus Removal in Cerebral Ischemia trials.
venous fibrinolysis, even though emergency physicians are most commonly the first to evaluate these patients. There are many unanswered questions about the role of imaging in defining best treatment. Perfusion imaging with CT or MRI appears to have relevance even though its role remains undefined and is the subject of ongoing research. Meanwhile, investigators are exploring new, and perhaps more specific, imaging methods with cerebral metabolic rate of oxygen and cellular acid-base imbalance. There are currently 6 ongoing trials of stroke intervention, many with proprietary technologies and private funding, competing for the same patient population as multicenter trials funded by the NIH. At the same time, much of the interventional stroke treatment currently occurs outside of trials in the community and academic settings without the collection of much-needed data. Market forces will certainly shape future stroke therapy, but it is unclear whether the current combination of private and public funding for these endeavors is the best method of development.

Disclosures

None.

References


**Key Words:** cerebral revascularization ■ cerebrovascular accident ■ fibrinolysis ■ stroke, acute ■ thrombectomy ■ thrombolytic therapy
Current Status of Endovascular Stroke Treatment

Circulation. 2011;123:2591-2601
doi: 10.1161/CIRCULATIONAHA.110.971564
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/123/22/2591

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/